IP Library › Granted Patent US 10,787,493
Granted Patent B2
US 10,787,493 · App. 16/441,324 · Granted Sep 29, 2020

Targeted modified TNF family members

Inventors: Jan Tavernier (Balegem, BE); Jennyfer Bultinck (Ledeberg, BE); Frank Peelman (Gentbrugge, BE); Gilles Uze (Montpellier, FR)
Assignees: VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITË DE MONTPELLIER; CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
C07K14/525C07K16/2869C07K16/32A61K38/00A61K2039/505C07K2317/569C07K2319/00C07K2319/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,787,493
App. No.
16/441,324
Granted
Sep 29, 2020
Kind
B2
Abstract

The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains can-y one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.

Claims (20)

1. A composition comprising a proteinaceous construct, comprising

(i) a single chain polypeptide comprising three modified human TNFs, wherein:

each modified human TNF comprises a modified amino acid residue by substitution at the I97 position relative to wild type human TNF (SEQ ID NO: 14), the substitution being selected from A, Q and S

and the modified human TNFs have reduced affinity towards their receptor as compared to wild type human TNF; and

(ii) a targeting moiety that is an antibody or a variable domain of a camelid heavy chain antibody (VHH) directed to a neo-vasculature tissue or cancer tissue specific marker,

wherein the composition has significant biological activity towards cells that are targeted by the targeting moiety.

2. The composition of claim 1 , wherein the targeting moiety is a VHH.

3. The composition of claim 1 , wherein the targeting moiety is directed towards CD20.

4. The composition of claim 1 , wherein the targeting moiety is directed towards Her2.

5. The composition of claim 3 , wherein the targeting moiety is a VHH.

6. The composition of claim 4 , wherein the targeting moiety is a VHH.

7. The composition of claim 1 , wherein the 197 substitution is I97A.

8. The composition of claim 1 , wherein the 197 substitution is I97Q.

9. The composition of claim 1 , wherein the 197 substitution is I97S.

10. The composition of claim 5 , wherein the 197 substitution is I97A.

11. The composition of claim 5 , wherein the 197 substitution is I97Q.

12. The composition of claim 5 , wherein the 197 substitution is I97S.

13. The composition of claim 6 , wherein the 197 substitution is I97A.

14. The composition of claim 6 , wherein the 197 substitution is I97Q.

15. The composition of claim 6 , wherein the 197 substitution is I97S.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2020
From: TAVERNIER, JAN; BULTINCK, JENNYFER; PEELMAN, FRANK; UZE, GILLES
To: VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE MONTPELLIER 2; CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
Reel/Frame 053527/0641 →
MERGER AND CHANGE OF NAME Recorded Aug 18, 2020
From: UNIVERSITE MONTPELLIER 2; UNIVERSITE DE MONTPELLIER
To: UNIVERSITE DE MONTPELLIER
Reel/Frame 053527/0649 →
Priority Claims (1)
EP 13306046 · Jul 19, 2013 · regional
Continuity (4)
Continuation 16020469 · Jun 27, 2018
Continuation 15883925 · Jan 30, 2018
Division 14905354
Related Publication 20190367575A1 · Dec 5, 2019
Cited By (5)
US 12,351,614 US 12,410,225 US 12,576,127 US 12,583,941 US 12,655,186